Literature DB >> 22187318

Outcome of kidney allograft in patients with adulthood-onset focal segmental glomerulosclerosis: comparison with childhood-onset FSGS.

Jin Ho Hwang1, Seung Seok Han, Wooseong Huh, Su-Kil Park, Dong Jin Joo, Myoung Soo Kim, Yu Seun Kim, Sang-Il Min, Jongwon Ha, Sang Joon Kim, Suhnggwon Kim, Yon Su Kim.   

Abstract

BACKGROUND: Idiopathic focal segmental glomerulosclerosis (FSGS) occurring at young age is known to predispose to poor graft outcome, but the outcome of adulthood-onset FSGS (A-FSGS) has not been thoroughly investigated. Here, we compared the graft outcomes between kidney recipients with A-FSGS and childhood-onset FSGS (C-FSGS).
METHODS: We enrolled 47 A-FSGS recipients and 60 C-FSGS recipients with an onset age of ≤ 15, from four of the largest transplant centers in Korea.
RESULTS: The baseline characteristics were similar between two groups. The 1- and 3-year cumulative recurrence rates were 20.0 and 22.1%, respectively. FSGS was recurrent in 19 C-FSGS patients [median duration, 2 months (interquartile range, IQR, 1-35)], and 11 patients had recurrent disease in A-FSGS [5 months (IQR, 3-37)]. The recurrence rate was similar between two groups (P = 0.126). The 5- and 10-year graft survival rates were 90.0 and 78.5%, respectively. The overall graft survival rates were not different between two groups. After adjusting baseline characteristics, the development of major outcomes was similar between two groups except acute rejection that was more frequent in A-FSGS. The age of disease onset did not affect recurrence in both groups. While grafts with recurrence had poorer graft survival in the A-FSGS group (P = 0.005), the recurrence was not associated with graft loss in the C-FSGS group (P = 0.558).
CONCLUSIONS: The onset age did not affect the graft outcome in patients with FSGS, and the recurrence significantly affected graft survival in A-FSGS. Therefore, the main focus should aim for the management of recurrence.

Entities:  

Mesh:

Year:  2011        PMID: 22187318     DOI: 10.1093/ndt/gfr699

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Long-Term Outcome of Kidney Transplantation in Recipients with Focal Segmental Glomerulosclerosis.

Authors:  Anna Francis; Peter Trnka; Steven J McTaggart
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-20       Impact factor: 8.237

2.  Recurrent focal segmental glomerulosclerosis after kidney transplantation.

Authors:  Rebecca Trachtman; Simranjeet S Sran; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2015-02-19       Impact factor: 3.714

3.  Recurrence of FSGS after Kidney Transplantation in Adults.

Authors:  Audrey Uffing; Maria José Pérez-Sáez; Marilda Mazzali; Roberto C Manfro; Andrea Carla Bauer; Frederico de Sottomaior Drumond; Michelle M O'Shaughnessy; Xingxing S Cheng; Kuo-Kai Chin; Carlucci G Ventura; Fabiana Agena; Elias David-Neto; Juliana B Mansur; Gianna Mastroianni Kirsztajn; Helio Tedesco-Silva; Gilberto M V Neto; Carlos Arias-Cabrales; Anna Buxeda; Mathilde Bugnazet; Thomas Jouve; Paolo Malvezzi; Enver Akalin; Omar Alani; Nikhil Agrawal; Gaetano La Manna; Giorgia Comai; Claudia Bini; Saif A Muhsin; Miguel Carlos Riella; Silvia R Hokazono; Samira S Farouk; Meredith Haverly; Suraj Sarvode Mothi; Stefan P Berger; Paolo Cravedi; Leonardo V Riella
Journal:  Clin J Am Soc Nephrol       Date:  2020-01-23       Impact factor: 8.237

4.  Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients.

Authors:  Hoon Suk Park; Yuah Hong; In O Sun; Byung Ha Chung; Hyung Wook Kim; Bum Soon Choi; Cheol Whee Park; Dong Chan Jin; Yong Soo Kim; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2014-06-27       Impact factor: 2.884

Review 5.  Recurrence and Treatment after Renal Transplantation in Children with FSGS.

Authors:  Hee Gyung Kang; Il-Soo Ha; Hae Il Cheong
Journal:  Biomed Res Int       Date:  2016-04-24       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.